Best Practice & Research in Clinical Rheumatology

Papers
(The H4-Index of Best Practice & Research in Clinical Rheumatology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy131
Exercise and inflammation100
Clinical manifestations and treatment of antisynthetase syndrome56
Role of diet in hyperuricemia and gout54
Diffuse idiopathic skeletal hyperostosis: Etiology and clinical relevance50
The epidemiology of psoriatic arthritis: A literature review42
Global health policy in the 21st century: Challenges and opportunities to arrest the global disability burden from musculoskeletal health conditions41
The interplay between neutrophils, complement, and microthrombi in COVID-1934
Musculoskeletal health in the workplace34
Cardiac involvement in systemic sclerosis: Getting to the heart of the matter34
Systemic autoinflammatory diseases: Clinical state of the art33
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes27
Hypertrophic osteoarthropathy26
Innovations to improve access to musculoskeletal care25
Managing patients using telerheumatology: Lessons from a pandemic25
Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus – A systematic literature review25
Implementing models of care for musculoskeletal conditions in health systems to support value-based care25
Risk assessment tools for osteoporosis and fractures in 202224
Allopurinol hypersensitivity: Pathogenesis and prevention23
Current status of imaging of Sjogren's syndrome23
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc22
Symptomatic joint hypermobility21
Primary hyperparathyroidism21
0.022707939147949